Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms

Published:2019-11-19 Issue:2 Volume:159 Page:167-177
ISSN:0019-2805
Container-title:Immunology
language:en
Short-container-title:Immunology

Author:

Fessas Petros¹,Possamai Lucia A.²,Clark James¹,Daniels Ella³,Gudd Cathrin²,Mullish Benjamin H.²,Alexander James L.²,Pinato David J.¹^ORCID

Affiliation:

1. Department of Surgery and Cancer Faculty of Medicine Imperial College London Hammersmith Hospital London UK

2. Department of Metabolism, Digestion and Reproduction Faculty of Medicine Imperial College London St Mary’s Hospital London UK

3. National Centre for HIV Malignancy Department of Oncology Chelsea and Westminster Hospital London UK

Funder

Cancer Research UK

National Institute for Health Research

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/imm.13141

Reference108 articles.

1. Pneumotoxicity associated with immune checkpoint inhibitor therapies

2. Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

3. Corrections to “Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

4. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

5. Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multidisciplinary Delphi Consensus on Safety of Combining Transarterial Radioembolization with Yttrium-90 Microspheres with Systemic Anticancer Agents for the Treatment of Liver Malignancy;Journal of Vascular and Interventional Radiology;2024-09

2. From immune dysregulation to organ dysfunction: understanding the enigma of Sepsis;Frontiers in Microbiology;2024-08-26

3. Prolonged Complete Remission Using Tislelizumab for Hepatocellular Carcinoma After Adjuvant Chemotherapy Failure: A Case Report;Journal of Hepatocellular Carcinoma;2024-06

4. Impact of Nutritional Status on Neutrophil-to-Lymphocyte Ratio as a Predictor of Efficacy and Adverse Events of Immune Check-Point Inhibitors;Cancers;2024-05-09

5. Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab;Targeted Oncology;2024-04-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3